Concepedia

Jacky Van Dun

JV

Statistics

Publications

22

Citations

768

H-Index

16

Active since

1984

Affiliations

Janssen (Belgium)(Current)

Johnson & Johnson (France)

Johnson & Johnson (United States)

Johnson & Johnson (Brazil)

Springhouse

Jacky Van Dun is an author at Janssen (Belgium) specializing in medicine, pharmacology, and drug discovery.

Top concepts

Publications per year

1984–2009

22

Publications

22

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies

Janine Arts, Patrick Angibaud, Ann Mariën et al. · British Journal of Cancer · 2007 · 89 citations · Full text

R 76713, a new specific non-steroidal aromatase inhibitor

Walter Wouters, R. De Coster, Marita D.W.G. Krekels et al. · Journal of Steroid Biochemistry · 1989 · 86 citations

, , +6

Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity

J Van heusden, R. Van Ginckel, Hélène Bruwiere et al. · British Journal of Cancer · 2002 · 83 citations · Full text

Effects of liarozole, a new antitumoral compound, on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells.

Walter Wouters, Jacky Van Dun, Ann Dillen et al. · PubMed · 1992 · 83 citations

, , +15

Design and Analysis of Drug Combination Experiments

Roel Straetemans, Timothy E. O’Brien, Luc Wouters et al. · Biometrical Journal · 2005 · 78 citations

1–5 of 22